Kymera director sells 3,000 shares after option exercise
Kymera Therapeutics director Elena Ridloff reported an exercise-and-sale transaction in company stock.
Rhea-AI Filing Summary
Kymera Therapeutics director Elena Ridloff reported an exercise-and-sale transaction in company stock. She exercised stock options for 3,000 shares of common stock at $31.20 per share and sold 3,000 shares in an open-market transaction at $87.00 per share. Following these trades, her direct common stock holdings reported in this filing are zero, while 13,000 stock options remain outstanding and exercisable, expiring on June 17, 2034. The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated December 11, 2025, indicating they were scheduled in advance.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 3,000 shares ($167K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Ridloff Elena
Role
Director
Sold
3,000 shs ($261K)
Approx. gross sale proceeds
$261K
Approx. exercise cost
$94K
Approx. pre-tax spread
$167K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 3,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,000 | $31.20 | $94K |
| Sale | Common Stock | 3,000 | $87.00 | $261K |
Holdings After Transaction:
Stock Option (Right to Buy) — 13,000 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (2)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person.
- F2. The shares underlying this stock option are fully vested and exercisable.
Key Figures
Shares sold: 3,000 shares
Sale price: $87.00 per share
Option exercise size: 3,000 shares
+2 more
5 metrics
Shares sold
3,000 shares
Open-market sale of common stock at $87.00 on May 11, 2026
Sale price
$87.00 per share
Price for 3,000 common shares sold on May 11, 2026
Option exercise size
3,000 shares
Shares acquired via stock option exercise on May 11, 2026
Option exercise price
$31.20 per share
Exercise price for stock options converted into 3,000 common shares
Options remaining
13,000 options
Stock options outstanding after transaction, expiring June 17, 2034
Key Terms
Rule 10b5-1 trading plan, open-market sale, Stock Option (Right to Buy), Exercise or conversion of derivative security
4 terms
Rule 10b5-1 trading plan financial
"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Kymera Therapeutics (KYMR) disclose for Elena Ridloff?
Kymera Therapeutics disclosed that director Elena Ridloff exercised options for 3,000 common shares at $31.20 and sold 3,000 shares at $87.00. This combination represents an exercise-and-sale pattern executed on the same date.
Did Elena Ridloff exercise Kymera Therapeutics (KYMR) stock options in this Form 4?
Yes. She exercised stock options covering 3,000 Kymera Therapeutics common shares at an exercise price of $31.20 per share. The shares obtained from this option exercise were then matched by a 3,000-share open-market sale on the same date.
What Kymera Therapeutics (KYMR) equity position does Elena Ridloff retain after these transactions?
After the reported transactions, her Form 4 shows no directly held common shares and 13,000 stock options outstanding. These options are fully vested, exercisable, and scheduled to expire on June 17, 2034, based on the filing details.
Were Elena Ridloff’s Kymera Therapeutics (KYMR) trades made under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan dated December 11, 2025. Such plans pre-schedule trades, indicating these transactions were arranged in advance rather than timed discretely by the insider.
AI-generated analysis. How Rhea-AI works. Not financial advice.
